• Je něco špatně v tomto záznamu ?

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party

A. Radujkovic, S. Dietrich, HJ. Blok, A. Nagler, F. Ayuk, J. Finke, J. Tischer, J. Mayer, Y. Koc, F. Sorà, J. Passweg, JL. Byrne, P. Jindra, JH. Veelken, G. Socié, J. Maertens, N. Schaap, M. Stadler, M. Itälä-Remes, E. Tholouli, M. Arat, V....

. 2019 ; 25 (10) : 2008-2016. [pub] 20190701

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025597

The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patients allografted for BC CML, focusing on patients with active disease at transplant and pretransplant prognostic factors. One hundred seventy patients allografted for BC CML after tyrosine kinase inhibitor pretreatment between 2004 and 2016 were analyzed. Before transplant, 95 patients were in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, active BC at transplant was the strongest factor associated with decreased overall survival (hazrd ratio, 1.87; P = .010) and shorter leukemia-free survival (LFS; hazard ratio, 1.69; P = .017). For patients with BC in remission at transplant, advanced age (≥45 years), lower performance status (≤80%), longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active BC, only UD transplant was significantly associated with prolonged LFS and trended toward improved overall survival. In summary, survival of patients allografted for BC CML was strongly dependent on pretransplant remission status. In patients with remission of BC, conventional prognostic factors remained the major determinants of outcome, whereas in those with active BC at transplant, UD transplant was associated with prolonged LFS in our study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025597
003      
CZ-PrNML
005      
20201222155305.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbmt.2019.06.028 $2 doi
035    __
$a (PubMed)31271884
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Radujkovic, Aleksandar $u Department of Internal Medicine V; University of Heidelberg, Heidelberg, Germany. Electronic address: aleksandar.radujkovic@med.uni-heidelberg.de.
245    10
$a Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party / $c A. Radujkovic, S. Dietrich, HJ. Blok, A. Nagler, F. Ayuk, J. Finke, J. Tischer, J. Mayer, Y. Koc, F. Sorà, J. Passweg, JL. Byrne, P. Jindra, JH. Veelken, G. Socié, J. Maertens, N. Schaap, M. Stadler, M. Itälä-Remes, E. Tholouli, M. Arat, V. Rocha, P. Ljungman, I. Yakoub-Agha, N. Kröger, Y. Chalandon,
520    9_
$a The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patients allografted for BC CML, focusing on patients with active disease at transplant and pretransplant prognostic factors. One hundred seventy patients allografted for BC CML after tyrosine kinase inhibitor pretreatment between 2004 and 2016 were analyzed. Before transplant, 95 patients were in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, active BC at transplant was the strongest factor associated with decreased overall survival (hazrd ratio, 1.87; P = .010) and shorter leukemia-free survival (LFS; hazard ratio, 1.69; P = .017). For patients with BC in remission at transplant, advanced age (≥45 years), lower performance status (≤80%), longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active BC, only UD transplant was significantly associated with prolonged LFS and trended toward improved overall survival. In summary, survival of patients allografted for BC CML was strongly dependent on pretransplant remission status. In patients with remission of BC, conventional prognostic factors remained the major determinants of outcome, whereas in those with active BC at transplant, UD transplant was associated with prolonged LFS in our study.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x terapie $7 D015464
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a příprava pacienta k transplantaci $x metody $7 D019172
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dietrich, Sascha $u Department of Internal Medicine V; University of Heidelberg, Heidelberg, Germany.
700    1_
$a Blok, Henric-Jan $u EBMT Data Office Leiden, Leiden, The Netherlands.
700    1_
$a Nagler, Arnon $u Chaim Sheba Medical Center, Tel-Hashomer, Israel.
700    1_
$a Ayuk, Francis $u University Hospital Eppendorf, Hamburg, Germany.
700    1_
$a Finke, Jürgen $u University of Freiburg, Freiburg, Germany.
700    1_
$a Tischer, Johanna $u Depariment of Internal Medicine III, University Hospital of Munich-Grosshadern, LMU, Munich, Germany.
700    1_
$a Mayer, Jiri $u Masaryk University Hospital Brno, Brno, Czech Republic.
700    1_
$a Koc, Yener $u Medical Park Hospitals, Antalya, Turkey.
700    1_
$a Sorà, Federica $u Universita Cattolica S. Cuore, Rome, Italy.
700    1_
$a Passweg, Jakob $u University Hospital, Basel, Switzerland.
700    1_
$a Byrne, Jenny L $u Nottingham University Hospital, Nottingham, United Kingdom.
700    1_
$a Jindra, Pavel $u Charles University Hospital, Pilsen, Czech Republic.
700    1_
$a Veelken, Joan Hendrik $u Leiden University Hospital, Leiden, The Netherlands.
700    1_
$a Socié, Gerard $u Hopital St. Louis, Paris, France.
700    1_
$a Maertens, Johan $u University Hospital Gasthuisberg, Leuven, Belgium.
700    1_
$a Schaap, Nicolaas $u Radboud University Medical Centre, Nijmegen, The Netherlands.
700    1_
$a Stadler, Michael $u Hannover Medical School, Hannover, Germany.
700    1_
$a Itälä-Remes, Maija $u HUCH Comprehensive Cancer Center, Helsinki, Finland.
700    1_
$a Tholouli, Eleni $u Manchester Royal Infirmary, Manchester, United Kingdom.
700    1_
$a Arat, Mutlu $u Florence Nightingale Sisli Hospital, Istanbul, Turkey.
700    1_
$a Rocha, Vanderson $u Hospital Sirio-Libanes, Sao Paulo, Brazil.
700    1_
$a Ljungman, Per $u Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, LIRIC, INSERM U995, Universite de Lille, Lille, France.
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany.
700    1_
$a Chalandon, Yves $u Division of Hematology, Department of Oncology, University Hospital, Geneva, Switzerland; Faculty of Medicine of Geneva, University of Geneva, Geneva Switzerland.
773    0_
$w MED00008579 $t Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation $x 1523-6536 $g Roč. 25, č. 10 (2019), s. 2008-2016
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31271884 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155301 $b ABA008
999    __
$a ok $b bmc $g 1599742 $s 1116283
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 25 $c 10 $d 2008-2016 $e 20190701 $i 1523-6536 $m Biology of blood and marrow transplantation $n Biol Blood Marrow Transplant $x MED00008579
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace